Replimune/$REPL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Ticker
$REPL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
479
ISIN
US76029N1063
Website
Replimune Metrics
BasicAdvanced
$830M
-
-$3.07
0.68
-
Price and volume
Market cap
$830M
Beta
0.68
52-week high
$14.80
52-week low
$6.44
Average daily volume
1.4M
Financial strength
Current ratio
7.952
Quick ratio
7.818
Long term debt to equity
17.358
Total debt to equity
18.316
Interest coverage (TTM)
-32.92%
Profitability
EBITDA (TTM)
-253.924
Effective tax rate (TTM)
-0.19%
Management effectiveness
Return on assets (TTM)
-31.26%
Return on equity (TTM)
-62.58%
Valuation
Price to book
2
Price to tangible book (TTM)
2
Price to free cash flow (TTM)
-4.362
Free cash flow yield (TTM)
-22.93%
Free cash flow per share (TTM)
-246.93%
Growth
Earnings per share change (TTM)
-5.31%
3-year earnings per share growth (CAGR)
10.73%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Bulls say / Bears say
Replimune's RP1 plus nivolumab combination therapy has shown promising results in treating anti-PD1 failed melanoma, with an objective response rate of 32.9% and a complete response rate of 15.0%, indicating strong potential for FDA approval and market adoption. (Replimune Press Release)
The FDA has accepted Replimune's Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review, with a PDUFA date set for July 22, 2025, suggesting a potential near-term commercialization. (Replimune Press Release)
Replimune has secured $96.7 million through a private investment in public equity (PIPE), bolstering its financial position to support the commercialization of RP1 and other corporate initiatives. (Replimune Press Release)
Replimune reported a net loss of $247.3 million for the fiscal year ended March 31, 2025, reflecting increased research and development expenses that may impact financial stability. (Replimune Press Release)
The company's cash, cash equivalents, and short-term investments decreased from $583.4 million as of March 31, 2023, to $483.8 million as of March 31, 2025, indicating a significant cash burn rate. (Replimune Press Release)
Despite promising clinical data, the success of RP1's commercialization is contingent upon FDA approval and market acceptance, both of which are uncertain and could affect future revenue streams. (Replimune Press Release)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Replimune News
AllArticlesVideos
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 month ago
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Replimune stock?
Replimune (REPL) has a market cap of $830M as of July 11, 2025.
What is the P/E ratio for Replimune stock?
The price to earnings (P/E) ratio for Replimune (REPL) stock is 0 as of July 11, 2025.
Does Replimune stock pay dividends?
No, Replimune (REPL) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Replimune dividend payment date?
Replimune (REPL) stock does not pay dividends to its shareholders.
What is the beta indicator for Replimune?
Replimune (REPL) has a beta rating of 0.68. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.